Literature DB >> 15610310

Which patients benefit from hemodialysis therapy in hepatorenal syndrome?

Oliver Witzke1, Markus Baumann, Daniel Patschan, Susann Patschan, Anna Mitchell, Ulrich Treichel, Guido Gerken, Thomas Philipp, Andreas Kribben.   

Abstract

BACKGROUND AND AIM: Hepatorenal syndrome (HRS) occurs in patients with advanced liver cirrhosis and has a poor outcome. The aim of the present study was to investigate which patients with HRS are likely to benefit from hemodialysis.
METHODS: Data were collected prospectively from 30 patients with Child-Pugh C liver cirrhosis and HRS. Patients were either treated with continuous veno-venous hemodialysis (CVVHD) if they were mechanically ventilated, or with intermittent hemodialysis (HD) if they were not mechanically ventilated. Prognosis was assessed by the Child-Pugh and by the Model for End-Stage Liver Disease (MELD) score. The primary aim of the study was the analysis of overall and 30-day patient survival during hemodialysis therapy. To identify predictive factors of survival, variables obtained before the initiation of dialysis therapy were evaluated.
RESULTS: Patients' 30-day survival was 8/30 (median survival time 21 days). Among patients treated with mechanical ventilation, 30-day survival time was 0/15 while 8/15 patients without mechanical ventilation survived more than 30 days (P < 0.001). Using a multivariate model, the relative hazards for serum albumin, international normalized ratio (INR) and catecholamine therapy were not different from one another (P > 0.05), indicating that these parameters were not independent predictors of survival. Mechanical ventilation was an independent risk factor for 30-day (relative hazard 6.6 [1.6-27.7], P < 0.001) and overall survival (relative hazard 6.3 [1.5-26.5], P = 0.01). Child-Pugh (P < 0.01) and the MELD (P < 0.01) score were predictive for overall survival independent of mechanical ventilation.
CONCLUSIONS: Patients with HRS without mechanical ventilation may benefit from hemodialysis, whereas hemodialysis seems to be futile in patients with mechanical ventilation.

Entities:  

Mesh:

Year:  2004        PMID: 15610310     DOI: 10.1111/j.1440-1746.2004.03471.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  29 in total

Review 1.  Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.

Authors:  Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

Review 2.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

Review 3.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 4.  [Hepatorenal syndrome].

Authors:  I Kürer; A Sommerer; G Puhl; U Kaisers; W Boemke
Journal:  Anaesthesist       Date:  2006-01       Impact factor: 1.041

Review 5.  Hepatorenal syndrome.

Authors:  Sharon Turban; Paul J Thuluvath; Mohamed G Atta
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

Review 6.  [Hepatorenal syndrome].

Authors:  G Huschak; U X Kaisers; S Laudi
Journal:  Anaesthesist       Date:  2013-07       Impact factor: 1.041

Review 7.  Acute kidney injury in acute on chronic liver failure.

Authors:  Rakhi Maiwall; S K Sarin; Richard Moreau
Journal:  Hepatol Int       Date:  2015-10-15       Impact factor: 6.047

8.  Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT.

Authors:  Andrew S Allegretti; Xavier Vela Parada; Nwamaka D Eneanya; Hannah Gilligan; Dihua Xu; Sophia Zhao; Jules L Dienstag; Raymond T Chung; Ravi I Thadhani
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-09       Impact factor: 8.237

Review 9.  [Cholestasis and liver dysfunction in critical care patients].

Authors:  M Kredel; J Brederlau; N Roewer; C Wunder
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

10.  Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.

Authors:  Tien Dong; Andrew Aronsohn; K Gautham Reddy; Helen S Te
Journal:  Dig Dis Sci       Date:  2016-09-21       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.